Gland Pharma Gains USFDA Tentative Approval for Eye Solution

Gland Pharma Limited has announced the receipt of tentative approval from the United States Food and Drug Administration (USFDA) for its Brimonidine Tartrate Ophthalmic Solution, 0.025% (OTC). This approval pertains to the company’s Abbreviated New Drug Application for the product, which is bioequivalent and therapeutically equivalent to the reference listed drug, Lumify Ophthalmic Solution, 0.025%, by Bausch & Lomb Inc. The product is indicated for the relief of eye redness.

The product’s market performance is notable, with US sales reaching approximately USD 39 million for the twelve months ending September 2025, according to IQVIA data. This financial figure underscores the product’s significant presence in the market. The tentative approval allows Gland Pharma to prepare for potential market entry, pending final approval.

The scope of the approval includes the manufacturing and marketing of the Brimonidine Tartrate Ophthalmic Solution as an over-the-counter (OTC) product. The solution is designed to provide therapeutic benefits equivalent to the existing market leader, Lumify. The approval process involves rigorous evaluation to ensure the product meets the necessary safety and efficacy standards set by the USFDA.

Gland Pharma’s strategic focus on ophthalmic solutions is part of its broader business model, which emphasizes the development and marketing of sterile injectables. The company operates primarily under a business-to-business (B2B) model and has established a global footprint across 60 countries, including the United States, Europe, Canada, and Australia. This approval aligns with Gland Pharma’s ongoing efforts to expand its product portfolio in the ophthalmic segment.

The timeline for the final approval and subsequent market launch will depend on the completion of the USFDA’s review process. Gland Pharma will continue to comply with all regulatory requirements to facilitate the transition from tentative to full approval. The company remains committed to maintaining high standards in its manufacturing and quality assurance processes.

Gland Pharma Limited, established in 1978, has evolved from a contract manufacturer of small-volume liquid parenteral products to one of the largest injectable-focused companies globally. It has a diverse range of products, including vials, ampoules, pre-filled syringes, lyophilized vials, dry powders, infusions, oncology, and ophthalmic solutions. The company is recognized for pioneering Heparin technology in India and continues to focus on expanding its product offerings and market reach.